Table II.

Base-case results of cost-effectiveness and cost-benefit analyses

Outcomes	Screening	No screening
Intermediate outcomes
Total cost of screening and diagnosis following screening	$741 376	N/A
Cost of screening and diagnosis per infant screened	$8.16	N/A
Treatment costs for infants receiving definitive treatment	$197 258	$457 401
Treatment costs for infants dying prior to definitive treatment	$27 234	$83 996
Treatment cost reduction with screening	$316 905	N/A
Net direct cost with screening	$424 470	N/A
Number of infants with SCID diagnosed preclinically	1.49	0.30
Number of additional SCID cases detected preclinically by screening	1.19	N/A
Number of cases of non-SCID TCL detected by screening	6.19	N/A
Number of infant deaths because of SCID	0.18	0.58
Number of deaths averted by screening	0.40	N/A
Discounted life-years gained by screening	12.02	N/A
Results of CEA
ICER (cost per life-y saved)	$35 311
Results of CBA (VSL = $9.0 million)
Total benefits (treatment cost reduction plus survival benefit)	3.94 million
Net benefit (benefits minus costs of screening and diagnosis)	3.19 million
Benefit-cost ratio	5.31
Results of CBA (VSL = $4.2 million)
Total benefits (treatment cost reduction plus survival benefit)	2.01 million
Net benefit (benefits minus costs of screening and diagnosis)	1.26 million
Benefit-cost ratio	2.71

N/A, not applicable.